Business
Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results
- Continued focus on advancing SGT-001 includes additional patient dosings in IGNITE DMD expected to begin in Q4 2021 - - Continued progress with SGT-003;
About this update from Solid Biosciences Inc.
[{"type":"text","content":"- Continued focus on advancing SGT-001 includes additional patient dosings in IGNITE DMD expected to begin in Q4 2021 - - Continued progress with SGT-003; Solid’s next-generation Duchenne gene therapy program demonstrates enhanced muscle tropism and microdystrophin expression - - Company ends Q3 with approximately $229.8 million in cash and investments; cash runway into Q2 2023 - CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today provided a business update as well as financial results for the third quarter ended September 30, 2021. “Solid made progress across all its strategic priorities during the third quarter. We expect to dose additional patients in IGNITE DMD beginning in the fourth quarter of 2021. We also shared meaningful clinical data across a variety of endpoints from the ongoing IGNITE DMD clinical trial of SGT-001, which continue to guide our understanding of the potentially differentiated benefit that SGT-001 may offer to patients. In addition, we advanced our Duchenne pipeline program, SGT-003, including selecting a manufacturing approach that will allow us to quickly move into human proof of concept in early 2023,” said Ilan Ganot, Chief Executive Officer, President and Co-Founder of Solid Biosciences. “As we prepare to dose additional patients in IGNITE DMD, we enter the fourth quarter with a great deal of excitement and momentum around our opportunities to improve outcomes for patients with Duchenne.” SGT-001 UpdateSolid expects to dose additional patients in IGNITE DMD, beginning in the fourth quarter of 2021. In addition, the company expects to report 90-day biopsy data from the first three patients dosed with SGT-001 manufactured with its improved process as well as long-term expression and functional data in early 2022. Concurrent with activities to support continued patient dosing in IGNITE DMD, Solid is also engaged in a variety of activities to support continued advancement of SGT-001, including scaling its improved manufacturing process. In September 2021, the Company reported 1.5-year data from IGNITE DMD at the World Muscle Society 2021 Virtual Congress and additional pulmonary function results from IGNITE DMD at the Child Neurology Society 50th Ann...